DC Advisory acts as financial advisor to Cinven on its strategic investment in Regenity Biosciences, adding a new partner alongside Linden Capital Partners

Background

• Founded in 1997 and headquartered in New Jersey, USA, Regenity Biosciences has spent nearly 30 years advancing innovative biomaterials that support the body’s natural healing processes for tissue and bone regeneration across multiple clinical areas, including dental, orthopedic, spine, neurosurgery, advanced wound, sports medicine, ENT, and nerve repair
• Regenity has an established history of product development and manufacturing, demonstrated by a broad portfolio of FDA-approved solutions and over 100 patents, with more than 5 million patients treated in 2025 and over 30 million patients treated since its founding
• Regenity’s team of more than 250 employees serves over 125 customers with over 80 product lines globally
• Cinven is a leading international private equity firm focused on building world-class global and European companies
• Linden Capital Partners is a Chicago-based private equity firm focused exclusively on the healthcare industry

Process

• DC Advisory served as the buy‑side advisor to Cinven on its strategic investment in Regenity
• DC Advisory leveraged its deep sector expertise in the regenerative MedTech and biomaterials sectors to provide strategic insights to Cinven in its evaluation of Regenity, including valuation framing and value creation strategy

Outcome

• The transaction closed in April 2026; the financial terms of the transaction were not disclosed
• The investment establishes a partnership between Cinven and Linden, reflecting their shared commitment to supporting high-quality healthcare businesses
• The firms will partner with Regenity’s management team to further enhance its longstanding track record of success in developing and commercializing innovative products and next-generation technologies alongside its strategic customers
• Cinven is well positioned to act as a strategic partner, leveraging its broad pan European presence alongside Regenity’s operational strength to accelerate innovation and drive growth across a large and rapidly expanding sector
• This transaction highlights DC Advisory’s deep expertise in the regenerative MedTech and biomaterials sector and marks the US Healthcare team’s third transaction in this sector and its 20th healthcare transaction since January 2024